Uncategorized

Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3

Regeneron misses again as melanoma combo bows to Merck’s Keytruda in Phase 3

Published

on

The late-stage miss shakes analyst confidence in Regeneron’s clinical execution, according to BMO Capital Markets, also noting last year’s Phase 3 failure in chronic obstructive pulmonary disease.​ ​Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version